RxDoctor Payments Data

Cheryl Trager, PA

Medical · Smithfield, RINPI 1003873001

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2023 at $397 and has fallen 58.3% since, to $166 in 2025.

$1,319in general payments, 2019–2025

Across 58 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$368
  • Pfizer$169
  • AstraZeneca$110
  • Vanda Pharmaceuticals Inc.$90
  • Genentech USA, Inc.$85
  • GSK$78
  • plus $419 from 9 others

What the payments were for

  • Food & beverage$1,319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,319 in reported general payments places this provider in the 70th percentile of 77 medical providers in Rhode Island.

See all medical providers in Rhode Island

Medicare billing

Part B allowed, 2024
$40,865
Medicare patients
274
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav159$1,636
Ofloxacin35$925
Albuterol Sulfate HfaAlbuterol Sulfate36$886
Doxycycline Monohydrate45$782
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$611
Prednisone226$448
Cephalexin40$426
Doxycycline Hyclate29$347
Cefdinir14$284
Azithromycin55$219
Mupirocin19$180
Ibuprofen36$175
Tizanidine Hcl34$173
Fluconazole14$133
Ondansetron OdtOndansetron19$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$169$032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 medical providers in Rhode Island.

Other medical in Smithfield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →